EP1397162A2 - Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats - Google Patents
Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugatsInfo
- Publication number
- EP1397162A2 EP1397162A2 EP02762293A EP02762293A EP1397162A2 EP 1397162 A2 EP1397162 A2 EP 1397162A2 EP 02762293 A EP02762293 A EP 02762293A EP 02762293 A EP02762293 A EP 02762293A EP 1397162 A2 EP1397162 A2 EP 1397162A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibiotic
- starch
- hydroxyethyl starch
- derivative
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B35/00—Preparation of derivatives of amylopectin
- C08B35/06—Ether-esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/02—Esters
- C08B31/04—Esters of organic acids, e.g. alkenyl-succinated starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/08—Ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/08—Ethers
- C08B31/12—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch
- C08B31/125—Ethers having alkyl or cycloalkyl radicals substituted by heteroatoms, e.g. hydroxyalkyl or carboxyalkyl starch having a substituent containing at least one nitrogen atom, e.g. cationic starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/16—Ether-esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B33/00—Preparation of derivatives of amylose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B33/00—Preparation of derivatives of amylose
- C08B33/02—Esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B33/00—Preparation of derivatives of amylose
- C08B33/04—Ethers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B33/00—Preparation of derivatives of amylose
- C08B33/06—Ether-esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B35/00—Preparation of derivatives of amylopectin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B35/00—Preparation of derivatives of amylopectin
- C08B35/02—Esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B35/00—Preparation of derivatives of amylopectin
- C08B35/04—Ethers
Definitions
- the present invention relates to water-soluble, orally or parenterally administrable preparations of antibiotics having an amino sugar in the form of a conjugate with a polysaccharide based on starch or starch derivatives, in particular hydroxyethyl starch and hydroxypropyl starch, and a process for their cost-effective production in high yield. Hydroxyethyl starch is particularly preferred as the polysaccharide.
- Antibiotics with an amino sugar are in particular amphotericin B, daunorubicin and doxorubicin, all of which have an amino group in the C 3 position of the amino sugar portion.
- Amphotericin B is mainly administered parenterally, daunorubicin and doxorubicin must be used IV. be administered.
- Amphotericin B is a polyen antibiotic isolated from Streptomyces nodosus. Chemically, it is a macrocyclic lactone (macrolide) with 7 conjugated double bonds in an all-trans configuration within a 38-membered lactone ring, to which the amino sugar D-mycosamine is bound via an O-glycosidic bond.
- Amphotericin B is amphoteric and has lipophilic and hydrophilic regions in the molecule, which enable it to form complexes with the sterols contained in the cytoplasmic membrane of fungi, which leads to a disturbance in cell permeability. Since bacterial membranes do not contain sterols, the antibiotic effect of Amphotericin B is selectively directed against fungi.
- Amphotericin B Because of the broad spectrum of action of Amphotericin B, which covers practically all human pathogenic fungi, it is the method of choice for systemic treatment of mycotic infections in humans. Especially in patients whose immune system is impaired, e.g. in HIV or cancer patients, the treatment of the associated invasive fungal infections has increased significantly in recent years.
- Amphotericin B is sometimes associated with rather massive side effects.
- amphotericin B i.v. applied usually with a daily dose of 0.5 to 0.7 mg / kg body weight.
- the dosage must be adjusted or adjusted individually.
- patients with a weakened immune system usually need higher doses than usual, e.g. 1 mg / kg body weight daily, which can be increased up to 1.5 mg / kg in difficult forms - if tolerable.
- the parenteral duration of use can extend from a few weeks to several months.
- Amphotericin B Because of its toxicity and side effects, Amphotericin B should therefore only be administered in life-threatening circumstances. On the other hand, however, it is caused by disorders caused by the immune system - e.g. in AIDS or after organ transplants - mycoses often the only effective remedy.
- amphotericin as a whole has pronounced hydrophobic properties, so that it is practically insoluble in water in the physiological pH range. It is difficult to dissolve even in organic solvents. Therefore, the current commercial preparations are relatively complicated pharmaceutical forms, which have additional disadvantages.
- a suitable solution mediator e.g. Na deoxycholate
- the solubility in water can be increased.
- the BRISTOL-MYERS SQUIBB originator preparation intended for infusion available in Germany under the trade name "Amphotericin B”
- Amphotericin B the stock solution thus obtained can only be used with electrolyte-free carrier solutions, e.g. a 5% glucose solution, diluted to the desired final concentration.
- This preparation also has a low therapeutic index, i.e. the window between the effective and toxic dose is very narrow.
- this preparation is not very effective in certain clinical pictures because the active substance does not reach the site of the mycotic infection or only in too small a concentration, so that amphotericin B does not or only has its characteristic antifungal activity can unfold insufficiently.
- amphotericin B preparations which represent lipid formulations, for example lipid complexes with amphotericin B, colloidal dispersions of cholesteryl sulfate with amphotericin B and liposomally packaged amphotericin B. All of these medicinal forms are shown Although a larger therapeutic index and a higher tolerance, in particular a lower nephrotoxicity compared to a conventional amphotericin B deoxycholate formulation, which is why they can also be administered in higher doses, the side effects described above cannot be avoided entirely at high doses ,
- amphotericin B As a further method of converting amphotericin B into a water-soluble form for injection purposes, the formation of an amphotericin B-arabinogalactan conjugate is described in the literature (Antimicrobial Agents and Chemotherapy, Vol. 43 No. 8, 1999, 1975-1981).
- Arabinogalactan is a water-soluble polysaccharide obtained from larch from arabinose and galactose units in a ratio of 1: 6.
- Amphotericin B binds to arabinogalactan in 4 steps. Arabinogalactan is first subjected to periodate oxidation, with vicinal hydroxyl groups of the sugar units being converted into dialdehydes with ring cleavage.
- the aminos group of mycosamine from amphotericin B is coupled to an aldehyde group to form an imine (Schiff base) and finally the imine group is converted into an amine group by means of Na borohydride. Group and unreacted aldehyde groups converted into hydroxyl groups.
- the coupling reaction is carried out at pH 11. This pH value is a compromise between the yield of the conjugate formed on the one hand and the toxicity of the conjugate on the other. Below pH 10, amphotericin B is water-insoluble and the yields are low. From pH 12, amphotericin B is relatively readily water-soluble, which enables higher yields, but the product obtained is toxic. Toxicity was also observed when the final step of Na borohydride reduction was omitted.
- the antibiotics daunorubicin and doxorubicin belong to the group of anthracyclines and differ only by a hydroxyl group. They are soluble in water. Doxorubicin is obtained from cultures of the fungus Streptomyces peuceticus var. Caesius, Daunomycin from Streptomyces peuceticus or coeruleorubidus.
- daunorubicin and doxorubicin are able to inhibit DNA and RNA synthesis with the formation of very stable, long-lasting DNA intercalation complexes.
- cytochrome P-450 reductase and NADPH they form semiquinone radicals, which in turn trigger further radical reactions (superoxide anion and hadroxyl radicals). This gives these antibiotics a pronounced cytostatic effect, which is why they are used as cytostatics in cancer therapy.
- antibiotics are only insufficiently absorbed after oral administration, they must be (strictly) IV. in short infusions over 10 to 15 minutes. They are distributed quickly in the organism, with the highest concentrations in the heart, lungs, spleen and kidneys being detected.
- the object of the present invention is therefore to provide pharmaceutical forms for such amino sugar-containing antibiotics in which the specific toxic side effects are reduced, which ensure a more uniform, controlled distribution in the organism and thus allow a higher dosage and which are nevertheless easy to use.
- Another object of the invention is to provide an inexpensive method for producing these dosage forms with a high yield.
- Starch or starch derivatives can be solved with such antibiotics.
- composition is a water-soluble antibiotic derivative containing an aminosugar
- polysaccharide portion of the conjugate is linked to the amino group at C 3 of the amino sugar of the antibiotic to form a peptide bond.
- starch or starch derivatives are amylose (unbranched only with ⁇ -l, 4-glycosidic linkage) and / or amylopectin (branched, additionally with ⁇ -l, 6-glycosidic linkage) and in particular hydroxyalkylated starch.
- amylose or amylopectin commercially available so-called "soluble" starch is used. The latter can also be in hydroxyethylated and hydroxypropylated form.
- the average molecular weight can be in the range between 2000 and 2 ⁇ 10 6 daltons.
- the average degree of polymerization should, however, be at least 15 and in a preferred one Embodiment range up to about 3000 (corresponding to an average molecular weight of about 5 • 10 5 ).
- the use of hydroxyethyl starch is particularly preferred.
- the molecular weight of the HES should preferably be above the kidney threshold for HES, ie above 70,000 Daltons.
- a HES of specification 130 / with an average molecular weight of 130,000 daltons is particularly preferred.
- the degree of substitution MS is preferably in the range from 0.1 to 0.8. In a preferred embodiment, the degree of substitution is in the range from 0.3 to 0.5.
- the preferred C 2 / C 6 ratio is in the range from 2 to 12, in a particularly preferred embodiment in the range from 5 to 11.
- HES can be both unbranched are present only with predominantly ⁇ -1,4-glycosidic linkages and also branched with both ⁇ -1,4-glycosidic linkages and also ⁇ -1,6-glycosidic linkages.
- the binding of the polysaccharide to the amino group of the amino sugar of the antibiotic is carried out by oxidizing the free, reducing aldehyde group of the terminal polysaccharide molecule, preferably with J 2, to form an aldonic acid group, which in turn contains a free hydroxyl group of the terminal sugar unit. preferably on the C 4 atom of the terminal sugar unit, a lactone ring is formed which can then form a peptide bond with the amino group of the amino sugar of the antibiotic.
- the coupling reaction according to the invention of the oxidation product at the reducing end of HES with the amino group of the amino sugar can also be used high yield in an organic solvent, for example DMSO, in which, for example, the antibiotic amphotericin B is soluble.
- the conjugate obtained surprisingly also proved to be non-toxic, so that it can also be administered orally.
- the conjugate can be dissolved or diluted to the desired applicable final concentration with electrolyte-containing solvents or mixtures (e.g. a mixture of isotonic saline and glucose solution).
- higher doses e.g. For the amphotericin B conjugate, apply daily doses of up to 15 mg of amphotericin B.
- hydroxyethyl starch can in any case be administered intravenously as a plasma expander in large doses, when HES and amphotericin B are coupled, unreacted portions of HES are physiologically harmless and therefore do not need to be separated from the reaction product, which is of great economic advantage in the synthesis.
- amphotericin B no final hydrogenation is required in order to make the conjugate formed less toxic.
- unbound hydroxyethyl starch itself on amphotericin B is even a solubilizing one Exerts an effect, whereby an additional stabilization of the antifungal active ingredient can be achieved with excess HES.
- an antibiotic-HES conjugate according to the invention is that the polysccharide portion is degradable by serum ⁇ -amylase. This degradation is described in detail in the relevant literature on the pharmacokinetics of the HES used as plasma expanders.
- the peptide bond between the polysaccharide component and the antibiotic in vivo is in principle accessible to an enzymatic attack.
- amphotericin B As was shown from studies on Candida albicans, known as the leading microorganism from the spectrum of the possible fungal infection germs, the conjugates of amphotericin B according to the invention had comparable efficacies to the lipid formulations. In the hemolysis test on sheep erythrocytes it was possible to demonstrate that the in vitro toxicity of an amphotericin B-HES conjugate is significantly lower than that of commercial amphotericin B deoxycholate formulations.
- a significant advantage of an antibiotic-HES conjugate according to the invention can be seen in the fact that the pharmacokinetic properties of the conjugate obtained can be adjusted practically tailored to the needs of a particular patient by suitable selection of molecular weight, degree of substitution, substitution pattern and degree of branching of the HES used.
- the solution obtained is then passed through an H + ion exchange column (Amberlite IR 120) and then dialyzed against distilled water in a dialysis tube with an exclusion limit of 4-6 kD over a period of 20 h.
- the dialyzed product is lyophilized and the degree of oxidation is determined using the SOMOGYI method.
- the method of SOMOGYI was used to determine the oxidized HES (ox-HES) formed (Meth. Carbohydrate Chem., 1, 384-386, 1962). The method is based on the determination of the free aldehyde groups via the reduction of Cu 2+ to Cu + . Cu ⁇ is oxidized again to Cu 2+ with the aid of iodine formed from iodide and iodate. Excess iodine is then titrated using thiosulfate.
- amphotericin B-HES conjugates obtained were characterized by their UV spectrum (0.5 g / 5 ml H 2 O dcst ) and showed the bands typical for polymeric or micellar interactions of amphotericin B in the range of 300-400 nm. In contrast to free amphotericin B, which is practically insoluble in water, the amphotericin-HES conjugates obtained had a water solubility of> 0.1 g / 5 ml H 2 0.
- Weight average molecular weight M w 102,700
- This characteristic data essentially corresponded to the characteristic data of the HES used.
- amphotericin B from Bristol-Meyers-Squibb, batch name: A068
- Amphotericin B from Bristol-Meyers-Squibb, batch name: A068
- the active ingredient of which is said to be hemolytic from a concentration of 8 ⁇ g / ml
- Stock solution for preparation according to the invention 1 1.61 g of Ampho-HES (corresponding to a weight fraction of 50 mg of amphotericin B) were dissolved in 50 ml of 5% glucose solution (batch number: 9233A4 from Braun Melsungen). The active substance content of the stock solution thus prepared was 1 mg of amphotericin B per ml. Three dilutions of this stock solution were prepared in accordance with Table 2 and also examined for their haemolytic effect.
- amphotericin B deoxycholate formulation A 50 mg bottle was washed with 10 ml A. a. injectabilia (lot number: 0514A63 from Braun Melsungen) and diluted in 5% glucose solution to 0.12 mg / ml amphotericin B.
- Hemolysis comparison test 5 ml each of the solutions to be tested were mixed with 1 ml of the above erythrocyte suspension, transferred to a cleaned centrifuge tube and incubated for 20 minutes in a water bath at 37 ⁇ 1 ° C. The mixture was then centrifuged for 5 minutes at a relative centrifugal acceleration of 2000.
- the absorbance of the supernatant was measured. 5 ml of the 0.9% NaCl solution and the 5% glucose solution, which were mixed with 1 ml the erythrocyte suspension was mixed, also incubated for 20 minutes at 37 ⁇ 1 ° C and then centrifuged as above.
- the absorbances of the respective supernatants against the negative controls were measured at a wavelength of 576 nm using a cuvette with a 10 mm layer thickness. Due to the different colorations of the solutions, the extinction was also measured for comparison of the solutions without erythrocyte suspension.
- the tested, commercially available amphotericin B deoxycholate formulation shows a strong haemolytic effect even at a concentration of 0.1 mg / ml in the test mixture under the above test conditions.
- the supernatant had an absorbance of 2.271 at 576 nm and was colored strongly red.
- ampho-HES preparation according to the invention had no hemolytic effect up to a concentration of 0.2 mg amphotericin B per ml observe. Only at a concentration of 0.4 mg / ml was there a slight red color in the supernatant of the test mixture compared to the negative control, which was also noticeable in the absorbance values. At this amphotericin B concentration in the test mixture, there is a slight hemolytic activity.
- the test preparation showed a strong hemolytic activity at a concentration of 0.83 mg / ml, where the supernatant was colored strongly red. In addition, microscopic few intact erythrocytes were found in the supernatant, which could not sediment into the pellet due to the high viscosity during the sedimentation period.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10129369 | 2001-06-21 | ||
DE10129369A DE10129369C1 (de) | 2001-06-21 | 2001-06-21 | Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats |
PCT/EP2002/006764 WO2003000738A2 (de) | 2001-06-21 | 2002-06-19 | Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1397162A2 true EP1397162A2 (de) | 2004-03-17 |
Family
ID=7688583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02762293A Withdrawn EP1397162A2 (de) | 2001-06-21 | 2002-06-19 | Wasserlösliches, einen aminozucker aufweisendes antibiotikum in form eines polysaccharidkonjugats |
Country Status (9)
Country | Link |
---|---|
US (1) | US7115576B2 (xx) |
EP (1) | EP1397162A2 (xx) |
JP (1) | JP2004534086A (xx) |
CN (1) | CN1596129A (xx) |
AU (1) | AU2002328294A1 (xx) |
CA (1) | CA2446205A1 (xx) |
DE (1) | DE10129369C1 (xx) |
PL (1) | PL366438A1 (xx) |
WO (1) | WO2003000738A2 (xx) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10112825A1 (de) | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
DE10209822A1 (de) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
DE10242076A1 (de) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | HAS-Allergen-Konjugate |
RU2329274C2 (ru) | 2002-09-11 | 2008-07-20 | Фрезениус Каби Дойчланд Гмбх | Способ получения производных гидроксиалкилкрахмала |
ES2314238T3 (es) | 2002-10-08 | 2009-03-16 | Fresenius Kabi Deutschland Gmbh | Conjugados de oligosacaridos farmaceuticamente activos. |
DE10256558A1 (de) * | 2002-12-04 | 2004-09-16 | Supramol Parenteral Colloids Gmbh | Ester von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe |
DE10302520A1 (de) * | 2003-01-23 | 2004-08-05 | Supramol Parenteral Colloids Gmbh | Kohlensäurediester von Stärkefraktionen und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe |
DE10324710A1 (de) * | 2003-05-30 | 2004-12-16 | Supramol Parenteral Colloids Gmbh | Stärkederivatkomplexe |
SG145746A1 (en) * | 2003-08-08 | 2008-09-29 | Fresenius Kabi De Gmbh | Conjugates of hydroxyalkyl starch and g-csf |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
BRPI0412671A (pt) * | 2003-08-08 | 2006-10-03 | Fresenius Kabi De Gmbh | conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima |
TWI417303B (zh) | 2004-03-11 | 2013-12-01 | Fresenius Kabi De Gmbh | 經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物 |
EP1732609B1 (en) * | 2004-03-11 | 2012-07-11 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein |
TW200603818A (en) * | 2004-03-11 | 2006-02-01 | Fresenius Kabi De Gmbh | Conjugates of hydroxyethyl starch and erythropoietin |
KR20070110902A (ko) * | 2005-03-11 | 2007-11-20 | 프레제니우스 카비 도이치란트 게엠베하 | 비활성 출발 물질로부터 생물활성 당단백질의 생산 |
EP1762250A1 (en) * | 2005-09-12 | 2007-03-14 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
CN101045163B (zh) * | 2006-03-29 | 2011-03-30 | 重庆莱美药业股份有限公司 | 一种高分子抗癌前药及其制备方法和用途 |
DE102006020035A1 (de) * | 2006-04-26 | 2007-10-31 | B. Braun Melsungen Ag | Herstellung und Verwendung von Poly(hydroxyethylstärke)chitin- und Poly(Carboxymethylstärke)chitin-Verbindungen |
CN1973902B (zh) * | 2006-12-12 | 2010-11-10 | 东北师范大学 | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 |
CN100569296C (zh) * | 2007-09-17 | 2009-12-16 | 重庆莱美药业股份有限公司 | 一种抗癌前药及其制备方法和用途 |
EP2070950A1 (en) | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
EP2070951A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Method for producing a hydroxyalkyl starch derivatives with two linkers |
EP2274331B1 (en) | 2008-05-02 | 2013-11-06 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
WO2011061747A1 (en) | 2009-11-23 | 2011-05-26 | Conjugate Ltd. | Antifungal and anti parasitic conjugates of amphotericin b derivatives |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
US20130178437A1 (en) * | 2010-07-09 | 2013-07-11 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
US9243049B2 (en) | 2011-08-09 | 2016-01-26 | Uab Profarma | Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof |
PL221351B1 (pl) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Sposób otrzymywania nanocząstek polisacharydowych |
CN104055787B (zh) | 2013-07-25 | 2017-04-26 | 北京蓝贝望生物医药科技股份有限公司 | 药用水溶性抗真菌大分子化合物 |
IL271777B2 (en) | 2017-07-07 | 2024-09-01 | Epicentrx Inc | Preparations for intravenous administration of medical substances |
CN110669087B (zh) * | 2018-07-02 | 2023-03-31 | 上海医药工业研究院 | 两性霉素b肽衍生物及其制备方法 |
US11028113B2 (en) * | 2018-10-26 | 2021-06-08 | Wisconsin Alumni Research Foundation | Cyphomycin, compositions and uses thereof |
WO2020119773A1 (zh) * | 2018-12-13 | 2020-06-18 | 上海医药工业研究院 | 两性霉素b肽衍生物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6045163B2 (ja) * | 1977-07-01 | 1985-10-08 | 協和醗酵工業株式会社 | 新規組成物 |
MY104520A (en) * | 1989-11-15 | 1994-04-30 | Novartis Ag | Polymyxin conjugates. |
GB2270920B (en) * | 1992-09-25 | 1997-04-02 | Univ Keele | Alginate-bioactive agent conjugates |
DE19628705A1 (de) | 1996-07-08 | 1998-01-15 | Fresenius Ag | Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe |
US5939016A (en) | 1996-08-22 | 1999-08-17 | Quantum Catalytics, L.L.C. | Apparatus and method for tapping a molten metal bath |
US6011008A (en) * | 1997-01-08 | 2000-01-04 | Yissum Research Developement Company Of The Hebrew University Of Jerusalem | Conjugates of biologically active substances |
US6338843B1 (en) * | 1997-06-12 | 2002-01-15 | Ml Laboratories | Biologically active materials |
NZ515999A (en) | 1999-06-18 | 2004-03-26 | Ml Lab Plc | Biologically active materials |
AU2001266201A1 (en) * | 2000-07-01 | 2002-01-14 | M.L. Laboratories Plc | Medicaments |
DE10112825A1 (de) | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
US20040234497A1 (en) | 2001-05-04 | 2004-11-25 | Yi Luo | Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells |
-
2001
- 2001-06-21 DE DE10129369A patent/DE10129369C1/de not_active Expired - Fee Related
-
2002
- 2002-06-19 PL PL02366438A patent/PL366438A1/xx unknown
- 2002-06-19 CA CA002446205A patent/CA2446205A1/en not_active Abandoned
- 2002-06-19 AU AU2002328294A patent/AU2002328294A1/en not_active Abandoned
- 2002-06-19 CN CNA028121953A patent/CN1596129A/zh active Pending
- 2002-06-19 EP EP02762293A patent/EP1397162A2/de not_active Withdrawn
- 2002-06-19 WO PCT/EP2002/006764 patent/WO2003000738A2/de active Application Filing
- 2002-06-19 JP JP2003507141A patent/JP2004534086A/ja active Pending
- 2002-06-19 US US10/481,597 patent/US7115576B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO03000738A2 * |
Also Published As
Publication number | Publication date |
---|---|
DE10129369C1 (de) | 2003-03-06 |
WO2003000738A3 (de) | 2003-08-28 |
PL366438A1 (en) | 2005-02-07 |
CA2446205A1 (en) | 2003-01-03 |
CN1596129A (zh) | 2005-03-16 |
US20040180858A1 (en) | 2004-09-16 |
WO2003000738A2 (de) | 2003-01-03 |
US7115576B2 (en) | 2006-10-03 |
AU2002328294A1 (en) | 2003-01-08 |
JP2004534086A (ja) | 2004-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10129369C1 (de) | Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats | |
DE69529288T2 (de) | Wasserlösliche polyen-konjugate | |
DE69430126T2 (de) | Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts | |
EP0149197B2 (de) | Pharmazeutische Präparate von in Wasser schwerlöslichen oder instabilen Arzneistoffen und Verfahren zu ihrer Herstellung | |
EP1480681B1 (de) | Kopplung niedermolekularer substanzen an hydroxyalkylstärke | |
DE69029006T2 (de) | Wasserlösliche hochmolekulare polymere Arzneistoffzubereitung | |
DE69130165T2 (de) | Cyclodextrinderivate mit erhöhter wasserlöslichkeit sowie deren verwendung | |
DE2845326C2 (de) | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung | |
EP1429789B1 (de) | Antiinfektive kohlenhydrate | |
DE69625326T2 (de) | Anthracyclinderivate und sie enthaldende medizinische zubereitungen | |
DE60307249T2 (de) | Eisen-dextrin verbindung zur behandlung von anämien durch eisenmangel | |
DE2701405C2 (de) | Triferridoxorubicin, Verfahren zu dessen Herstellung und diese Verbindung enthaltendes pharmazeutisches Mittel | |
DE60024601T2 (de) | Dispergierbare zusammensetzungen von macroliden und verfahren zu deren herstellung | |
DE69730902T2 (de) | Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes | |
DE69128760T2 (de) | Antidiarrhoeika | |
DE69012747T2 (de) | Polymyxinkonjugate. | |
DE69412760T2 (de) | Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen | |
DE69425948T2 (de) | Zusammensetzung mit verbesserter Wasserlöslichkeit, enthaltend eine Wasserunlösliche oder an Wasser schwerunlösliche Verbindung | |
DE69833487T2 (de) | Polymer-wirkstoff-konjugate zur behandlung von krebs | |
DE69423683T2 (de) | Cyclodextrin Einschluskomplexe mit Taxol, ein Verfahren zu ihrer Herstellung und ihre Anwendung | |
DE10155098A1 (de) | Mittel zur Prävention von mykotischen Kontaminationen bei der Zell- und Gewebekultur bakteriellen, pflanzlichen, animalischen und humanen Ursprungs, bestehend aus Polyen-Makrolid-Konjugaten mit Polysacchariden | |
DE69103869T2 (de) | Arzneizubereitung mit verzögerter Wirkstoffabgabe auf Basis von Platin enthaltenden Antikrebsmitteln. | |
DE2926463C2 (xx) | ||
DE4207922A1 (de) | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung | |
EP0147851B1 (de) | Wasserlösliche Formen von Polyenantibiotika und Verfahren zu ihrer Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031016 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20070807 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110319 |